| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 79111 |
MC-Val-Cit-PAB-Indibulin，cas:2055896-95-0，ADC定制 |
99 |
wyh |
2024-12-19 |
| 79112 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
104 |
zyl |
2024-12-19 |
| 79113 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
106 |
zyl |
2024-12-19 |
| 79114 |
MC-Sq-Cit-PAB-Dolastatin10 ，cas:1941168-65-5，ADC定制 |
112 |
wyh |
2024-12-19 |
| 79115 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
114 |
zyl |
2024-12-19 |
| 79116 |
N3-PEG4-DYKDDDD-Doxorubicin，ADC定制 |
122 |
wyh |
2024-12-19 |
| 79117 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
82 |
zyl |
2024-12-19 |
| 79118 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
136 |
zyl |
2024-12-19 |
| 79119 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
112 |
zyl |
2024-12-19 |
| 79120 |
MC-GGFG-DX8951 cas:1600418-29-8 |
94 |
zyl |
2024-12-19 |
| 79121 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
123 |
h |
2024-12-19 |
| 79122 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
228 |
zyl |
2024-12-19 |
| 79123 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
123 |
h |
2024-12-19 |
| 79124 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
151 |
h |
2024-12-19 |
| 79125 |
VC-SECO DUBA analogue，ADC定制 |
118 |
wyh |
2024-12-19 |
| 79126 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
107 |
h |
2024-12-19 |
| 79127 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
176 |
h |
2024-12-19 |
| 79128 |
Vc-MMAD cas:1401963-17-4的结构式 |
96 |
zyl |
2024-12-19 |
| 79129 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
128 |
h |
2024-12-19 |
| 79130 |
CL2A-SN38，cas:1279680-68-0，ADC定制 |
211 |
wyh |
2024-12-19 |
| 79131 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
105 |
h |
2024-12-19 |
| 79132 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
179 |
h |
2024-12-19 |
| 79133 |
MC-MMAF ， cas:863971-19-1，ADC定制 |
127 |
wyh |
2024-12-19 |
| 79134 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
170 |
zyl |
2024-12-19 |
| 79135 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
127 |
h |
2024-12-19 |
| 79136 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
125 |
h |
2024-12-19 |
| 79137 |
Vc-MMAE， cas:646502-53-6，ADC定制 |
176 |
wyh |
2024-12-19 |
| 79138 |
Azido-PEG4-MMAE |
133 |
zyl |
2024-12-19 |
| 79139 |
cas:2055024-59-2，Fmoc-PEG2-Val-Cit-PAB-OH |
135 |
zyl |
2024-12-19 |
| 79140 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin，ADC定制 |
137 |
wyh |
2024-12-19 |
| 79141 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
90 |
h |
2024-12-19 |
| 79142 |
cas:1807530-16-0，2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
140 |
zyl |
2024-12-19 |
| 79143 |
DOTA偶联受体特异性肽 |
139 |
h |
2024-12-19 |
| 79144 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
136 |
h |
2024-12-19 |
| 79145 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
132 |
h |
2024-12-19 |
| 79146 |
ALD-tetra-EG-Osu的介绍 |
154 |
zyl |
2024-12-19 |
| 79147 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
269 |
h |
2024-12-19 |
| 79148 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
122 |
h |
2024-12-19 |
| 79149 |
cas:55750-63-5，Mal-heptanoic NHS ester |
149 |
zyl |
2024-12-19 |
| 79150 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
130 |
h |
2024-12-19 |
| 79151 |
cas:663599-10-8，DMAC-SPP |
130 |
zyl |
2024-12-19 |
| 79152 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
172 |
h |
2024-12-19 |
| 79153 |
PEG-pGlu(DOTA)8-LA4 |
74 |
h |
2024-12-19 |
| 79154 |
cas:937025-17-7，2,5-Dioxopyrrolidin-1-yl 2-oxo-6,9,12,15-tetraoxa-3-thiaoctadecan-18-oate |
164 |
zyl |
2024-12-19 |
| 79155 |
DOTA-Hyd-TRP PET示踪剂 |
130 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询